14th Annual Liver Transplantation Symposium

Saturday, Dec. 8, 2018

The Hotel Hershey
100 Hotel Road
Hershey, PA 17033

Select this button to navigate the sections of this page

Conference ID



This conference is designed to provide updated information about liver transplantation, including pre- and post-transplant considerations.


Gastroenterologists, hepatologists, radiologists, physicians in the primary care setting with patients who have liver failure or are transplant recipients, nurses, nurse practitioners and physician assistants may all benefit from attendance.



Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Penn State College of Medicine designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses Using AMA Credit

Nurses will receive a certificate from Penn State College of Medicine verifying their participation in 4.75 hours of approved continuing medical education. Continuing education activities which are approved by accredited institutions of higher education and that are relevant to patient care or professional nursing meet the requirements of mandatory continuing education for registered nurses in Pennsylvania, as required by the Pennsylvania State Board of Nursing. The Board of Nursing recommends that nurses retain their certificates for a period of at least five years. Additional information is available through the State Board of Nursing website.

Transplant Certification

The American Board for Transplant Certification has approved our program for 4.75 CEPTC Category 1 Continuing Education Points for Transplant Certification.


8:30 a.m. to 3:45 p.m.

  • 8:30 a.m. | Check-In/Continental Breakfast/Visit Exhibitors
  • 9 a.m. | Welcome and Introductions
    Kofi Clarke, MD, FACP, FRCP (Lond)
  • 9:15 a.m. | The Changing Surgical Landscape in The Treatment of Liver Lesions: Resection or Transplantation?
    Zakiyah Kadry, MD, FACS

    • Identify liver transplant allocation for liver tumors.
    • Describe surgical evaluation, approach and treatment of liver lesions.
    • Explain immunosuppression for transplanted liver tumor patients.
  • 9:45 a.m. | Differential Diagnosis of Liver Mass
    Thomas R. Riley III, MD

    • Discuss the differential diagnosis of liver mass.
    • Describe the separation of cystic vs. solid mass.
    • Recognize the separation between malignant and benign liver masses.
  • 10:15 a.m. | Break/Exhibitors
  • 10:30 a.m. | Liver Masses: How to Tell Them Apart on Imaging
    Anita Ankola, MD

    • Review the classic imaging appearance of hepatocellular carcinoma on CT and MRI using the Liver Imaging Reporting and Data System (LI-RADS) major criteria.
    • Differentiate the MRI imaging appearance of common benign hepatic lesions from malignancy.
  • 11 a.m. | Incidentalomas: Evaluation and Management of Hepatic Adenoma vs. Focal Nodular Hyperplasia
    Jonathan G. Stine, MD, MSc, FACP

    • Differentiate hepatic adenomas from focal nodular hyperplasia (FNH) based on history, physical exam, laboratories and imaging studies.
    • Discuss the role of estrogen in the development and progression of hepatic adenomas and FNHs.
    • Review the evidence-based best clinical practices for management of hepatic adenomas and FNHs including the utility of liver transplantation for hepatic adenomatosis.
  • 11:30 a.m. | Patient Panel – Psych Aspects
    Facilitated by: Zakiyah Kadry, MD, FACS and Thomas R. Riley III, MD
  • 12:15 p.m. | Lunch/Visit Exhibitors
  • 1:30 p.m. | Hepatitis C (HCV), Hepatocellular Carcinoma (HCC) and the Law of Unintended Consequences
    Ian Roy Schreibman, MD, FAGA, FACG

    • Describe the efficacy of directly acting antiviral agents (DAA) for hepatitis C.
    • Discuss the importance of the diagnosis of hepatocellular carcinoma.
    • Identify the controversies involved in using DAAs in the setting of HCC.
  • 2 p.m. | Transplant Role/Allocation/Resection
    Karen Krok, MD

    • Identify the new models for end-stage liver disease (MELD) allocation system for HCC.
    • Explain outcomes of liver transplant for liver tumors.
    • Describe liver transplant for hepatic adenomatosis.
  • 2:30 p.m. | Break/Exhibitors
  • 2:45 p.m. | IR – Tace, RFA (EMBOLIZATION/Y-90)
    Peter N. Waybill, MD, FSIR

    • Identify lesions appropriate for percutaneous ablation.
    • Describe several different ablation techniques.
    • Explain indications for regional hepatic therapies.
  • 3:15 p.m. | Anesthesia for Complex Liver Resection (CVP)
    Thomas A. Verbeek, MBChB

    • Explore the impact of hepatic disease on perioperative physiology during major abdominal surgery.
    • Discuss the pros and cons of low intraoperative CVP.
    • Describe the value of enhanced recovery in liver surgery measures.
  • 3:45 p.m. | Closing Remarks/Program Adjournment


Course Directors

Zakiyah Kadry, MD, FACS
Thomas R. Riley III, MD

Planning Committee

Karen Krok, MD
Ian Roy Schreibman, MD, FAGA, FACG
Jonathan G. Stine, MD, MSC, FACP
Eileen Swartz, BSN, RN, CCTC

Faculty: Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine

Anita Ankola, MD
Assistant Professor of Radiology
Abdominal Imaging
Department of Radiology

Kofi Clarke, MD, FACP, FRCP (Lond)
Professor of Medicine
Department of Medicine
Division Chief
Gastroenterology and Hepatology

Zakiyah Kadry, MD, FACS
Professor of Surgery
Department of Surgery
Chief, Division of Transplantation
Surgical Director, Liver Transplantation

Karen Krok, MD
Associate Professor of Medicine
Director, Live Donor Liver Transplantation
Gastroenterology and Hepatology

Thomas R. Riley III, MD
Professor of Medicine
Medical Director
Liver Transplantation
Gastroenterology and Hepatology

Ian Roy Schreibman, MD, FAGA, FACG
Associate Professor of Medicine
Gastroenterology and Hepatology

Jonathan G. Stine, MD, MSC, FACP
Assistant Professor of Medicine
Gastroenterology and Hepatology

Thomas A. Verbeek, MBChB
Assistant Professor of Medicine
Anesthesiology and Perioperative Medicine

Peter N. Waybill, MD, FSIR
Professor of Radiology, Medicine and Surgery
Chief, Cardiovascular and Interventional Radiology
Director of Interventional Oncology


Fee is $65 per person, which includes instruction, all listed meals and online handout materials.

Registrations received after Dec. 7, 2018, will incur a $25 late fee.


Cancellations received after Nov. 30, 2018, will incur a $25 processing fee.

No refunds will be given after Dec. 4, 2018.

The University reserves the right to cancel or postpone any course or activity because of insufficient enrollment or other unforeseen circumstances. If a program is canceled or postponed, the University will refund registration fees but cannot be held responsible for any related costs, charges, or expenses, including cancellation/change charges assessed by airlines or travel agencies. Preregistered participants will be notified if a program is filled or canceled.


This program is a continuing education service of Penn State College of Medicine.

Save the Date

The 15th Annual Liver Transplantation Symposium will take place Dec. 7, 2019, at The Hotel Hershey, 100 Hotel Road, Hershey, PA 17033.

Access (ADA)

Penn State encourages persons with disabilities to participate in its programs and activities. If you anticipate needing any type of special accommodation or have questions about the physical access provided, please contact Continuing Education at least one week in advance of your participation or visit.


Content and speakers for all programs are subject to change. Registrants will be notified of any significant updates.

Disclosure and Conflict of Interest (COI and educational balance)

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Complete faculty disclosure will be provided to program participants at the beginning of the activity.

University Nondiscrimination Policy

This publication is available in alternative media on request. The Pennsylvania State University is committed to the policy that all persons shall have equal access to programs, facilities, admission, and employment without regard to personal characteristics not related to ability, performance, or qualifications as determined by University policy or by state or federal authorities. It is the policy of the University to maintain an academic and work environment free of discrimination, including harassment. The Pennsylvania State University prohibits discrimination and harassment against any person because of age, ancestry, color, disability or handicap, genetic information, national origin, race, religious creed, sex, sexual orientation, gender identity, or veteran status and retaliation due to the reporting of discrimination or harassment. Discrimination, harassment, or retaliation against faculty, staff, or students will not be tolerated at The Pennsylvania State University. Direct all inquiries regarding the Nondiscrimination Policy to the Affirmative Action Director, The Pennsylvania State University, 328 Boucke Building, University Park, PA 16802-5901; tel 814-863-0471/TTY. US M.Ed. J6253

Jump to ...